Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Epanutin

regeneron headquarters

Regeneron says anti-NGF fasinumab works in pain

Clinical trial shows promise for opioid alternative

- PMLiVE

Pfizer split still on cards – for tax reasons

Firm continues to look for ways to reduce tax burden

- PMLiVE

Paywatch and the market access waters

Understanding and responding to payers’ needs has become priority number one for pharma

- PMLiVE

Pfizer’s Champix and GSK’s Zyban cleared of causing neuropsychiatric side effects

EAGLES trial of 8,000 patients backs the smoking cessation drugs' safety

National Institute for Health and Care Excellence NICE logo

NICE changes tack on Sanofi’s prostate cancer drug Jevtana

Approves the therapy for NHS use after accepting undisclosed additional discount 

german flag

Germany planning to table pricing reforms ‘by the summer’

Proposed changes include replacing 12-month full price policy with €250m threshold

Celgene building

Celgene: Patient voice often underrepresented in pricing debates

Dr Jackie Fouse says in the interests of transparency patients should be more involved

- PMLiVE

Pfizer joins up with IBM for internet-of-things collaboration

Aims to develop an IoT remote monitoring system for Parkinson’s patients

- PMLiVE

Novel drugs and rare diseases drive US prescription drug spend

But increased competition and cost-cutting measures forced price concessions

- PMLiVE

Post-Shkreli KaloBios pledges transparent pricing

Will seek input from “key stakeholders” and share reasoning behind pricing of drugs

- PMLiVE

US tax changes claim Pfizer scalp as Allergan deal abandoned

Firm walks away from record-breaking $160bn merger after planned inversion rule changes released

- PMLiVE

FDA approves first Remicade biosimilar

Pfizer-Celltrion's Inflectra becomes the second biosimilar to be licensed in the US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links